Option chain shows key data for Longeveron's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Longeveron.

Longeveron (NASDAQ:LGVN) Stock, Option Chain

LONGEVERON INC-A

Longeveron

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Screenshot 2024-11-15 at 7.50.34 PM

Biotech

General

BCLI

BRTX

LGVN

MESO

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative&#39;s Inroads Bringing Its Stem Cell Therapies To Market

movers image

News

Pre-Market Outlook

Movers

ADSE

ARBB

EONR

HCTI

IBRX

INDO

JFBR

JTAI

LENZ

MNPR

NWTN

PXDT

TARS

TCBP

TVGN

UPXI

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Digital,Marketing,Data,Analytic,Technology,,Businessman,Using,Laptop,Computer,To

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

CRWD

KOSS

MIRA

MSFT

NUZE

NVDA

PLTR

SERV

SMCI

SOBR

TSLA

ZAPP

A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here&#39;s a look at the others.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?

Longeveron Inc

Press Releases

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Health Care

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Earnings

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron® to Attend BIO International Convention 2025

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Elevation Oncology

Evaxion

FibroGen

HOOKIPA Pharma

Imunon

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

MEI Pharma

Marker Therapeutics

Nanoviricides

Ovid Therapeutics

Passage Bio

Q32 Bio

Rallybio

SAB Biotherapeutics

HC Wainwright & Co.

Roth MKM

Maxim Group

EF Hutton

Comments

Longeveron

Longeveron (LGVN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell